Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Diabetes has become a leading cause of death worldwide. Although there is no cure for diabetes, blood glucose monitoring combined with appropriate medication can enhance treatment efficiency, alleviate the symptoms, as well as diminish the complications. For point-of-care purposes, continuous glucose monitoring (CGM) devices are considered to be the best candidates for diabetes therapy. This review focuses on current growth areas of CGM technologies, specifically focusing on subcutaneous implantable electrochemical glucose sensors. The superiority of CGM systems is introduced firstly, and then the strategies for fabrication of minimally-invasive and non-invasive CGM biosensors are discussed, respectively. Finally, we briefly outline the current status and future perspective for CGM systems.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298755 | PMC |
| http://dx.doi.org/10.3390/s17010182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Genetic analysis is essential for diagnosing, treating, and predicting complications in neonatal diabetes mellitus (NDM) but is unavailable in some regions. Sulfonylureas are effective for NDM caused by KCNJ11 or ABCC8 mutations, which are among the most common genetic causes, therefore they are often given before genetic testing. Unfortunately, in certain ethnicities, this mutation rarely occurs.
View Article and Find Full Text PDFTime below range alone is insufficient to identify severe hypoglycaemia risk in type 1 diabetes-the critical role of hypoglycaemia awareness: results from the SFDT1 study.
Diabetologia
September 2025
Centre Universitaire de Diabétologie et de ses Complications, AP-HP, Hôpital Lariboisière, Paris, France.
Aims/hypothesis: Severe hypoglycaemia events (SHE) remain frequent in people with type 1 diabetes despite advanced diabetes technologies. We examined whether time below range (TBR) 3.9 mmol/l (70 mg/dl; TBR70) or 3.
View Article and Find Full Text PDFFeasibility of High-Resolution Deuterium Metabolic Imaging of the Human Kidney Using Concentric Ring Trajectory Sampling at 7T.
NMR Biomed
October 2025
High-Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
The human kidneys play a pivotal role in regulating blood pressure, water, and salt homeostasis, but assessment of renal function typically requires invasive methods. Deuterium metabolic imaging (DMI) is a novel, noninvasive technique for mapping tissue-specific uptake and metabolism of deuterium-labeled tracers. This study evaluates the feasibility of renal DMI at 7-Tesla (7T) to track deuterium-labeled tracers with high spatial and temporal resolution, aiming to establish a foundation for potential clinical applications in the noninvasive investigation of renal physiology and pathophysiology.
View Article and Find Full Text PDF[Advanced Hybrid Closed Loop (AHCL) System for Glucose Monitoring and Automatic Insulin Microinfusion in Dialysis].
G Ital Nefrol
August 2025
Infermiere Professionale SSD Nefrologia e Dialisi P.O. Soverato, ASP CZ.
Management of diabetes mellitus in hemodialysis is highly complex due to increased glycemic variability and hypoglycemic risk. The use of technologies applied to diabetes has been shown to improve glycemic control, however data in dialysis patients are limited. To describe the efficacy and safety of the minimed 780G AHCL system in a stable hemodialysis patient and during hospitalization in the Intensive Care Unit (ICU).
View Article and Find Full Text PDFNoninvasive Monitoring of Blood Glucose With In Vivo Raman Spectroscopy.
J Biophotonics
September 2025
Institute of Photonics and Photon-Technology, Northwest University, Xi'an, China.
Non-invasive glucose monitoring using Raman spectroscopy with 830 nm excitation presents a promising alternative to traditional fingerstick methods for diabetes management research. An integrated in vivo Raman system enables transcutaneous glucose detection and has demonstrated robust performance in oral glucose tolerance tests (OGTT), validating its reliability. Inter-subject correlation between spectral features and glucose concentration was addressed by the intensity of the fingerprint peak (I), peak intensity ratio (I/I), and the spectral area ratio (S/S), whose correlation coefficient (R) was 0.
View Article and Find Full Text PDF